Floatz logo

PANITUMUMAB

Ischemic Heart Disease

Chinese Academy of Medical Sciences, Fuwai Hospitalmonoclonal_antibodyDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Ischemic Heart Disease cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
VALSARTAN
Kyoto Prefectural University of Medicine
Phase 4BB
WARFARIN
Columbia University
Phase 3BB
ELECLAZINE
Gilead Sciences
Phase 2CCC
Polycap
St. John's Research Institute
N/AD
Plavix
Bayer
D

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →